AGT owns companies headquartered in Argentina, or companies that have strong links to the country but that are headquartered and listed somewhere else. ARGT, too, includes companies listed outside of Argentina.
Both funds have less than 30 holdings each, are pretty narrow and don’t have significant assets, but they are both outperforming the broader emerging markets as measured by the iShares MSCI Emerging Markets ETF (EEM):
Health Care ETF Among Leaders?
Healthcare is the worst-performing S&P 500 sector this year. Investors have been concerned about Medicare-for-all and other types of sector reinvention are peppering presidential election debates.
But the Ark Genomic Revolution ETF (ARKG) is rallying sharply. The fund is bucking the downward trend in health care by focusing on companies that are supposed to help shape the sector’s future, including artificial intelligence, and companies on the forefront of clinical trials and diagnostics improvements. In a recent interview with ETF.com, Manisha Samy, genomics analyst at ARK, pinned the outperformance on stock choices.
“We seek to invest in biotech and genomics stocks focused on platform technologies that are decreasing costs of research while increasing novel scientific revelations,” she said. “We believe we’re in the early stages and are beginning to see proof that these treatment modalities are working.”
ARKG, with $448 million in assets and an expense ratio of 0.75%, has significantly outperformed the broader health care sector as measure by the Health Care Select Sector SPDR Fund (XLV):
Charts courtesy of StockCharts.com
Contact Cinthia Murphy at [email protected]